Biopta Closes £900,000 Investment To Grow Its Drug Development Services
Published: Dec 04, 2008
The investment will allow Biopta to greatly expand the range of services it offers and to grow its team of scientists, including the appointment of a Head of R&D who will lead the development of Biopta’s new range of human tissue based services. Claire Jenkins, Sales Director at Biopta said ”currently we are only scratching the surface of the human tissue research market and this investment will let us meet the demands of new and existing clients. As the only European human tissue based company with GLP (Good Laboratory Practice) accreditation we have a lead in the market”.
Investment in this round includes funding from Braveheart Investment Group and Scottish Enterprise’s Scottish Co-Investment Fund – both of which have previously invested in Biopta. Significant new investors have also come on board including Borders-based angel group, TriCap and private individuals. Elaine Ferguson, Finance Director at Biopta said ‘‘this investment is a great vote of confidence from both existing investors and new investors who recognise that Biopta has developed a strong brand as experts in human tissue research in an emerging market”
Biopta, founded in 2002 as spin-out of Glasgow Caledonian University, is a unique early development in vitro CRO (contract research organisation), providing novel services in fresh ex vivo human tissues to global pharmaceutical and biotechnology companies.
Biopta’s services improve the predictability and efficiency of drug development by providing ’Good Laboratory Practice’-compliant safety and efficacy services in ethically-donated human tissues. These highly predictive assays bridge the gap between cell-based screening and animal in vivo studies by providing powerful human data much earlier in the development process. Biopta aims to reduce the risk of late stage drug failures and add value to early stage compounds. For more information on Biopta, please visit www.biopta.com.